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Abstract 
Background: Angiotensin-II (Ang II) mediates progression of autosomal-dominant polycystic kidney disease (ADPKD) 
and other chronic kidney diseases (CKD). However, markers of kidney Ang II activity are lacking. We previously defined 
83 Ang II-regulated proteins in vitro, which reflected kidney Ang II activity in vivo.
Methods: In this study, we developed selected reaction monitoring (SRM) assays for quantification of Ang II-
regulated proteins in urine of ADPKD and CKD patients. We demonstrated that 47 of 83 Ang II-regulated transcripts 
were differentially expressed in cystic compared to normal kidney tissue. We then developed SRM assays for 18 Ang 
II-regulated proteins overexpressed in cysts and/or secreted in urine. Methods that yielded CV ≤ 6 % for control 
proteins, and recovery ~100 % were selected. Heavy-labeled peptides corresponding to 13 identified Ang II-regulated 
peptides were spiked into urine samples of 17 ADPKD patients, 9 patients with CKD predicted to have high kidney 
Ang II activity and 11 healthy subjects. Samples were then digested and analyzed on triple-quadrupole mass spec-
trometer in duplicates.
Resluts: Calibration curves demonstrated linearity (R2 > 0.99) and within-run CVs < 9 % in the concentration range 
of 7/13 peptides. Peptide concentrations were normalized by urine creatinine. Deamidated peptide forms were 
monitored, and accounted for <15 % of the final concentrations. Urine excretion rates of proteins BST1, LAMB2, LYPA1, 
RHOB and TSP1 were significantly different (p < 0.05, one-way ANOVA) between patients with CKD, those with ADPKD 
and healthy controls. Urine protein excretion rates were highest in CKD patients and lowest in ADPKD patients. 
Univariate analysis demonstrated significant association between urine protein excretion rates of most proteins and 
disease group (p < 0.05, ANOVA) as well as sex (p < 0.05, unpaired t test). Multivariate analysis across protein concen-
tration, age and sex demonstrated good separation between ADPKD and CKD patients.
Conclusions: We have optimized methods for quantification of Ang II-regulated proteins, and we demonstrated that 
they reflected differences in underlying kidney disease in this pilot study. High urine excretion of Ang II-regulated pro-
teins in CKD patients likely reflects high kidney Ang II activity. Low excretion in ADPKD appears related to lack of com-
munication between cysts and tubules. Future studies will determine whether urine excretion rate of Ang II-regulated 
proteins correlates with kidney Ang II activity in larger cohorts of chronic kidney disease patients.
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Background
Renin angiotensin system (RAS) activity within the kid-
ney plays a major role in the progression of most chronic 
kidney diseases, including polycystic kidney disease. The 
main effector of the RAS is angiotensin II (Ang II), an 
octapeptide that exerts diverse adverse hemodynamic 
and non-hemodynamic effects on the kidney, includ-
ing increased sodium reabsorption, increased vasocon-
striction, increased inflammation, oxidative stress, and 
fibrosis [1–7]. In autosomal-dominant polycystic kidney 
disease (ADPKD), a main form of polycystic kidney dis-
ease, Ang II plays a role in the pathogenesis of hyperten-
sion, and contributes to cyst growth [8, 9]. Cyst growth 
measured by magnetic resonance imaging (MRI) has 
been associated with ADPKD progression [10, 11]. 
Blockade of the RAS is the mainstay treatment of chronic 
kidney disease (CKD), and it has been shown to slow 
down progression of ADPKD [12–15]. However, over-
zealous RAS blockade may have serious adverse effects 
[16, 17]. Thus, monitoring of Ang II activity within the 
kidney would enable adequate dose-adjustments of RAS 
blockers, avoid the consequences of overly aggressive 
RAS blockade, and help estimate patient’s risk of kidney 
disease progression. Unfortunately, specific markers of 
kidney Ang II activity are lacking.
In clinical practice, it would be ideal to monitor mark-
ers of RAS and Ang II activity in a non-invasive biofluid 
such as urine. Recent literature addressing markers of 
RAS activity in the kidney has focused primarily on 
measuring urine excretion rates of angiotensinogen. 
Angiotensinogen is a precursor protein that is enzymati-
cally cleaved by renin to generate angiotensin I, which is 
subsequently cleaved by angiotensin converting enzyme 
(ACE) to generate Ang II. Several studies have reported 
increased urinary angiotensinogen excretion in patients 
with CKD, and in a few studies angiotensinogen excre-
tion correlated with CKD progression [18–20]. Studies 
of patients with ADPKD also echoed the potential link 
between urine angiotensinogen excretion and factors 
associated with progression, such as hypertension, eGFR 
and total kidney volume [21, 22]. Plasma angiotensino-
gen levels are poised near the Km for cleavage by renin, 
so that alteration of angiotensinogen levels also affects 
the formation of Ang II [23]. Nonetheless, kidney RAS 
is complex, and simple substrate measurements may 
not be indicative of true RAS bioactivity. This was most 
clearly demonstrated by Matsusaka and colleagues, who 
showed that kidney angiotensinogen levels can indeed be 
measured in urine of mice, however, it is the liver angi-
otensinogen that is enzymatically cleaved in proximal 
tubules of the kidney to generate Ang II [24, 25]. There is 
thus rationale to search for more specific markers of Ang 
II activity in the kidney, and we aim to fulfill this unmet 
clinical need.
We have previously identified 83 proteins differentially 
regulated by Ang II in primary human proximal tubu-
lar cells [26]. We verified differential expression of 18 of 
these 83 proteins by using selected reaction monitoring 
(SRM) in primary tubular cell lysates. Subsequently, we 
demonstrated that these Ang II-regulated proteins were 
differentially expressed in kidney tissue of two distinct 
mouse models of chronic kidney disease, and at least 
one top candidate protein was measurable in urine, and 
its excretion rate correlated with kidney Ang II levels 
[26, 27]. It is thus tempting to postulate that kidney tis-
sue expression of these Ang II-regulated proteins may 
reflect disease severity in human forms of chronic kidney 
disease. Furthermore, a subgroup of these Ang II-regu-
lated proteins may be excreted in urine, and their urinary 
excretion rate may correlate with disease severity and 
Ang II activity in the kidney. The aim of this study was 
to develop SRM-based assays for quantification of Ang 
II-regulated proteins in human urine. For method devel-
opment and initial pilot study, we utilized urine samples 




The reagents used in this study were as follows. Acetoni-
trile (HPLC grade) and ammonium bicarbonate were 
from Fisher Scientific (NJ, USA). Amicon® Ultra 3KDa 
centrifugal filters and formic acid were from EMD Mil-
lipore (Merck KGaA, Darmstadt, Germany). Proteomics-
grade trypsin, dithiotreitol, iodoacetamide, and bovine 
serum albumin (>98  % pure) were from Sigma-Aldrich 
(Oakville, ON, Canada). Proteomics-grade trypsin/lys-C 
mix was from Promega (Madison, WI, USA). Ultrapure 
grade urea was from Amresco (Solon, OH, USA). 
Ultrapure water was from Milli-Q (Millipore, Molsheim, 
France). Crude unlabeled, crude isotopically labeled 
(lysine: 6 × 13C, 2 × 15N, arginine: 8 × 13C, 2 × 15N) 
and purified isotopically labeled peptides were from JPT 
Peptide Technologies (Berlin, Germany). OMIX C18 
10 μl tips were from Agilent Technologies (Lake Forest, 
CA, USA).
Keywords: Angiotensin II, Renin angiotensin system, Polycystic kidney disease, Autosomal dominant polycystic 
kidney disease, Selected reaction monitoring, Proteomics, Urine, Chronic kidney disease
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Samples
Second morning spot urine samples (10–50  mL) were 
collected from 11 healthy volunteers, 17 patients with 
autosomal dominant polycystic kidney disease (ADPKD), 
and 9 patients with non-ADPKD chronic kidney dis-
ease (CKD). These samples were centrifuged at 1000g 
for 10 min at room temperature. The supernatants were 
transferred to a fresh tube, and immediately frozen at 
−80 °C. After thawing in 37 °C bath, urine samples were 
centrifuged at 2000g for 10 min at room temperature and 
debris was discarded. The supernatants were transferred 
to a fresh tube and the urinary protein concentration was 
measured by a clinical benzethonium chloride-based 
assay (Roche). Urine creatinine concentrations were 
determined by Jaffé colorimetric assay.
Study population
Patients with ADPKD and CKD were followed in the kid-
ney disease clinic by Dr. York Pei at Toronto General Hos-
pital in Toronto. Patients were selected from a research 
database, based on availability of urine sample. Healthy 
volunteers were selected as controls. Patients’ and controls’ 
characteristics are presented in Additional file 1: Table S1.
Selection of proteins and peptides for SRM method 
development
SRM methods were developed for those Ang II-regulated 
proteins with the highest likelihood of being found in 
urine and those previously monitored by SRM [26]. To 
determine presence in urine, we first searched publically 
available urine databases including: (1) Max-Planck Uni-
fied Proteome Database: http://www.mapuproteome.
com/urine/; (2) a publication documenting >400 proteins 
in human urine [28]; (3) Peptide Atlas Database (http://
www.peptideatlas.org); and (4) ExoCarta (http://www.
exocarta.org). We also searched PubMed for publications 
explicitly documenting the proteins of interest in urine. 
Ten Ang II-regulated proteins were discovered in urine 
when applying the search algorithm described (TSP1, 
GLUL, SPARC, TGFBR2, BST1, LYPLA1, LAMB2, 
HO1, RHOB and DBNL). Finally, we selected six addi-
tional Ang II-regulated proteins (PDCD4, ARHGEF2, 
VCPIP1, DNAJB4, TXNIP, and PHLDA1) that we previ-
ously monitored in human proximal tubular cells [26], 
and two additional Ang II-regulated proteins predicted to 
be secretory based on the signal sequence or transmem-
brane region (Signal IP algorithm; Human Protein Atlas: 
http://www.proteinatlas.org) (EGFR and RBM3). Most 
of the selected proteins were differentially expressed at 
mRNA level in cysts of patients with ADPKD, compared 
to minimally cystic or normal kidney tissue (as will be 
discussed in the results). Thus 18 proteins were selected 
for SRM method development (Table 1).
The experimental design is presented in Fig. 1. Two to 
three proteotypic peptides were selected for each of the 
18 proteins. Details regarding peptide selection, method 
development and data analysis have been published 
before [29]. The most highly observable peptides based on 
the +2 ions from Peptide Atlas were selected. Fully tryp-
tic and doubly charged peptides with 7–20 amino acids 
were chosen. Peptides with methionine, tryptophan, and 
N-terminal cysteine residues were avoided, whenever 
possible. All peptides were also analyzed with the protein 
Basic Local Alignment Search Tool (BLAST) (http://blast.
ncbi.nlm.nih.gov/Blast.cgi) to ensure that peptides were 
proteotypic to each protein. In this way we compiled a list 
of 37 proteotypic peptides for SRM method development. 
Skyline software was then used to select transitions con-
taining y ions from y +  3 to last ion-1 for each peptide 
in silico. We selected 301 transitions corresponding to our 
proteotypic peptides (5–8 transitions per peptide).
SRM method development
In the second step of method development (Fig.  1), we 
determined the retention time and the order of transi-
tions by intensity for each of the 37 peptides. In case of 
11/37 peptides, we had established retention times and 
order of transition intensities from the previous SRM 
experiments [26]. For the remaining 26/37 peptides, we 
purchased corresponding crude unlabeled synthetic pep-
tides that were subjected to reduction, alkylation, and 
trypsin digestion, as recommended by the manufacturer. 
The peptide mixture was subsequently concentrated by 
the OMIX C18 tip and analyzed by LC–MS/MS on triple 
quadrupole instrument, as described below.
SRM method optimization in human urine
In the third step of method development, we established 
and optimized a protocol for reproducible recovery of 
Ang II-regulated peptides. We started from healthy con-
trol urine aliquots (four per urine sample), each contain-
ing 100 μg of total protein. To assess reproducibility and 
recovery, we spiked in non-human protein, bovine serum 
albumin (BSA) at a known concentration of 1 μg (1 % of 
total protein). We then compared protein precipitation 
with acetonitrile to protein concentration with Amicon® 
Ultra 3KDa centrifugal filters (Fig.  1). Urine samples 
containing 100 μg of total protein and precipitated over-
night with acetonitrile at a ratio of 1:9 (v/v), were then 
centrifuged at 3220g for 30 min at 4 °C. The pellets were 
washed with acetonitrile twice, then air-dried. Pellets 
were then resuspended in 100  μL of denaturing buffer 
consisting of 8  M urea and 0.1  M ammonium bicar-
bonate. Denatured samples were reduced with 20  mM 
dithiotreitol in 50 mM ammonium bicarbonate at 37  °C 
for 30 min. Reduced samples were alkylated with 80 mM 
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iodoacetamide in 50  mM ammonium bicarbonate at 
room temperature for 30 min in the dark.
In parallel to precipitation with acetonitrile, we con-
centrated urine proteins with Amicon® Ultra 3KDa cen-
trifugal filters. We started from urine samples containing 
100 μg of total protein that were centrifuged in individual 
filters at 3220g for 60 min. Buffer exchange with 8 M urea 
was performed and filters were centrifuged for additional 
60  min. Finally, 100–200  μL of retentate was collected 
and subjected to reduction and alkylation as above.
Following reduction and alkylation, we compared pro-
tein digestion with trypsin to Lys-C/trypsin mix. Half of 
the aliquots precipitated with acetonitrile or concentrated 
with Amicon® filters were subjected to trypsin digestion 
(1:50 w/w) at 37 °C overnight. The second half of the ali-
quots were treated with Lys-C/trypsin (1:50  w/w) and 
incubated at 37 °C for 3 h. Urea concentration in aliquots 
was then reduced to 2 M by the addition of 0.1 M ammo-
nium bicarbonate, in order to enable trypsin digestion. 
Samples were then incubated at 37  °C overnight. In all 
cases, trypsin digestion was stopped by the addition of 1 % 
(v/v) formic acid. Samples were then vortexed and sepa-
rated into aliquots containing 20 μg of total protein. They 
were subsequently frozen at −20 °C until further analysis.
Table 1 Proteins selected for development of SRM assays in urine
Bold peptides were detected and selected for absolute quantification in human urine
a Proteins definitively found in urine in prior studies
b Proteins previously monitored by SRM in our study
c Proteins predicted to be secretory based on computational algorithm (SignalIP)
Protein/uniprot ID Uniprot ID Peptide amino acid sequence
Heme oxygenase-1 (HO-1)ab P09601 VQDSAPVETPR
TEPELLVAHAYTR
Thrombospondin-1 (TSP-1)ab P07996 TIVTTLQDSIR
GGVNDFQGVLQNVR
Glutamate-ammonia ligase(GLUL)a P15104 LTGFHETSNINDFSAGVANR
TCLLNETGDEPFQYK
LVLCEVFK
Ras homologue family member B (RHOB)ab P62745 LVVVGDGACGK
IQAYDYLECSAK
Osteonectin (SPARC)a P09486 YIPPCLDSELTEFPLR
FFETCDLDNDK
Transforming growth factor beta, receptor II (TGFBR2)a P37173 LDPTLSVDDLANSGQVGTAR
IFPYEEYASWK
Bone marrow stromal cell antigen 1 (BST1)a Q10588 GFFADYEIPNLQK
AGLIIPLFLVLASR
Lysophospholipase I (LYPA1)a O75608| ASFPQGPIGGANR
LAGVTALSCWLPLR
Laminin, beta 2 (LAMB2)a P55268 LQEGQTLEFLVASVPK
GSCYPATGDLLVGR
Drebrin-like (DBNL)ab Q9UJU6 VAGTGEGGLEEMVEELNSGK
FQDVGPQAPVGSVYQK
Programmed cell death 4 (PDCD4)b Q53EL6 APQLVGQFIAR
SGVPVLAVSLALEGK
Thioredoxin interacting protein (TXNIP)bc Q9H3M7 SFEVVFNDPEK
HTYLANGQTK
Pleckstrin-homology like domain, Family A, Member 1(PHLDA1)bc Q8WV24 AAGNGEAEPSGGPSYAGR
YMYFTVVMAFGK
Rho/Rac guanine nucleotide exchange factor 2 (ARHGEF2)b Q92974 DLLVGPGVELLLTPR
ELLSNVDEGIYQLEK
Hsp40 homologue, Subfamily B, Member 4 (DNAJB4)bc Q9UDY4 IIGYGLPFPK
EALCGCSINVPTLDGR
Valosin containing protein (p97)/p47 complex interacting protein (VCPIP1)b Q96JH7 TEPSVFTASSSNSELIR
SSGDYSATFLPGLIPAEK
Epidermal growth factor receptor (EGFR)c P00533 EISDGDVIISGNK
ELVEPLTPSGEAPNQALLR
RNA binding motif, protein 3 (RBM3)c P98179 YYDSRPGGYGYGYGR
GGGDQGYGSGR
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After thawing of individual aliquots containing 20  μg 
of total protein, we spiked in three crude heavy isotope 
labeled proteotypic peptides of BSA at a concentration 
of 100 fmol/μL. Samples were then desalted and concen-
trated using OMIX C18 10 μl tips.
SRM‑based detection of Ang II‑regulated proteins 
in human urine
Having optimized the methods for urine SRM based 
on the recovery and reproducibility of BSA peptides, 
we used these methods to monitor 37 Ang II-regulated 
peptides in two healthy urine samples, and nine urine 
samples from patients with ADPKD. The retention time 
and order of transition intensities determined during the 
analysis of crude unlabeled peptides was used for SRM 
scheduling, and to select the correct peptide peaks.
We successfully identified 13 of 37 peptides in all 
urine samples (Table 1), and we then purchased the cor-
responding purified 13 heavy-labeled peptides with a 
trypsin-cleavable tag, to correct for digestion efficiency. 
Samples were then prepared as shown in Fig.  2. All 
samples were analyzed on the same day in duplicates, 
to assess within-run precision, which was expressed as 
mean CV of all samples, for each individual peptide. In 
addition, we assessed between-day precision in all urine 
samples, which included thawing of a new sample ali-
quot of the same urine sample on a different day, spik-
ing in of BSA, precipitation of proteins, digestion, C18 
Fig. 1 Steps in SRM method development. I ANG II-regulated proteins most likely to be found in urine were selected for SRM method develop-
ment. Most highly observable proteotypic (unique) peptides were selected from Peptide Atlas, and searched with the protein BLAST (http://blast.
ncbi.nlm.nih.gov/Blast.cgi) to ensure their uniqueness. Transitions were then selected by in silico digestion in Skyline. II To develop SRM methods 
we purchased 26 crude, synthetic, unlabeled peptides, which were used to determine retention time and order of transitions. 11 additional pep-
tides had methods previously developed in human primary cells. III To determine reproducibility and recovery of sample preparation, we spiked 
1 µg of BSA protein into urine containing 100 µg of total protein. We examined four different sample preparation protocols: ACN precipitation, Ami-
con filter concentration, digestion with trypsin alone or digestion with Lys-C and trypsin. Finally we spiked in three heavy isotope-labeled peptides 
corresponding to BSA, and fractions containing 20 µg total protein were subjected to C18 microextraction, prior to injection on triple quadrupole
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microextraction, and analysis by LC-MS. This addressed 
variation due to sample preparation. Between-day preci-
sion was expressed as the mean CV of all samples ana-
lyzed on different days for each individual peptide. The 
samples were processed and run on mass spectrometry 
instrument in random order. Finally, calibration curves 
were generated, by spiking heavy-labeled peptides into 
the same urine sample at concentrations: 1000, 100, 10, 1, 
0.1, and 0 fmol/μL. Blank sample contained equal volume 
of buffer used to suspend heavy-labeled peptides. Limit 
of detection (LOD) and limit of quantification (LOQ) 
were calculated for each peptide. LOD was calculated by 
taking the average of blank injections and adding three 
standard deviations to the mean. LOQ was calculated 
by taking the average of blank injections and adding 10 
standard deviations to the mean.
Liquid chromatography mass spectrometry parameters
Concentrated peptides were loaded in a volume of 18 μL 
onto a 3.3  cm pre-column (C18, 5  μm) and eluted on a 
15  cm analytical column (C18, 3  μm). We used the fol-
lowing parameters: Flow rate  =  300  nl/min during 
gradient, C18 material: Agilent Pursuit 5  μm for pre-
column, 3  μm for analytical column; Precolumn ID: 
150 μm × 3.2 mm; Analytical column ID: 75 μm × 15 cm. 
The reversed-phase liquid chromatography (EASY-nLC, 
Proxeon, Odense, Denmark) was coupled to a triple-
quadrupole mass spectrometer (TSQ Quantiva, Thermo 
Fisher Scientific Inc., San Jose, CA) using a nanoelectro-
spray ionization source, as previously described [29–31]. 
Peptides were separated over 60  min, with a previously 
optimized 3-step gradient. We used Buffer A containing 
0.1  % formic acid, and Buffer B containing acetonitrile 
and 0.1 % formic acid. In the first step of method devel-
opment, 5–6 peptides and about 50 transitions were 
included in each survey SRM method and run in a non-
scheduled mode with 20 ms scan time per transition, on 
a 60-min gradient. Q1 was set to 0.2 Thompson FWHM 
(Th, Full Width Half Maximum), Q3 to 0.7 Th FWHM, 
and Q2 pressure was set to 1.5  mTorr. The instrument 
was run in a positive ion mode, with collision energies 
predicted by Skyline software, according to the follow-
ing formula: CE = 0.03 ×  (precursor m/z) + 2.905 [32]. 
Reproducibility of SRM signal was ensured by running a 
QC solution of 1 fmol/μL BSA every five runs.
After determining the retention times of our peptides 
of interest, we scheduled 10–15 peptides and approxi-
mately 80 transitions in each SRM method, with 20  ms 
scan time per transition, on a 60-min gradient. The 
other instrument parameters were unchanged. Final 
Fig. 2 Absolute quantification of Ang II-regulated proteins in human urine samples. ACN acetonitrile, BSA bovine serum albumin, Heavy labeled 
heavy isotope-labeled peptide
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optimizations included increasing Q1 to 0.4 Th, decreas-
ing scan time to 10  ms for abundant peptides, and 
increasing it to 30 ms for low abundance peptides.
Raw files recorded for each sample were analyzed using 
Skyline software [33], and CSV files with peptide areas 
were extracted. All peptides were manually inspected.
Study of chemical modifications
In addition to monitoring unmodified forms of Ang II-
regulated peptides, we examined for presence of oxi-
dized methionines and deamidated asparagines and 
glutamines. Urine samples from healthy subjects and 
ADPKD patients were first examined for the presence 
of these forms, and we subsequently monitored modi-
fied heavy and light (naturally occurring) forms that 
demonstrated significant abundance. Peptides with 
modifications and transitions monitored are displayed in 
Additional file 1: Table S2.
Data analysis
Skyline was used to verify the integration of chromato-
grams, and to calculate peptide areas. Light/heavy peak 
area intensity ratios were used to calculate concentra-
tions of peptides monitored, by using the equation: light/
heavy peptide ratio × heavy peptide concentration (fmol/
μL)  ×  volume of heavy peptides (μL)/(urine creatinine 
(μmol)  ×  dilution factor). Recovery of BSA peptides 
was calculated as: observed BSA amount/spiked-in BSA 
amount × 100 %. Observed BSA amount was calculated 
from: light/heavy peptide ratio × heavy peptide concen-
tration (fmol/μL) × volume of heavy peptides (μL).
Protein concentrations were first normalized by log2 
transformation and subsequent subtraction of the log2 
transformed concentrations of creatinine. For each of 
the proteins two sample t test was conducted to assess 
the significance of difference in the protein concentra-
tion between sexes (R’s function t.test). For each protein 
Pearson’s coefficient of correlation was calculated to eval-
uate correlation between concentration of the protein 
and age (R’s function cor). Significance of the correlation 
was then evaluated by cumulative distribution function 
of t distribution with n-2 degrees of freedom, where n is 
the number of measurements (R’s function cor.test). To 
assess the significance of differences of the protein con-
centration among sample types, for each protein we con-
ducted ANOVA (R’s function aov), followed by Tukey’s 
range test (a. k. a. Tukey’s honest significance differences) 
to assess significance of differences between individual 
pairs of sample types (R’s function TukeyHSD). Finally 
multiple correspondence analysis (MCA) was performed 
on protein concentration and clinical data including sex 
and age, where all protein concentrations as well as age 
were first discretized into four levels each, in a way that 
preserves equal frequencies between levels. All steps 
were performed in R version 3.1.2. Two-tailed p value 
<0.05 was considered significant. GraphPad Prism soft-
ware version 5 (GraphPad Software, Inc. La Jolla, CA) 
was used to display calibration curves and calculate 
regression equations.
For analyses of mRNA expression of Ang II-regulated 
proteins in polycystic kidneys compared to normal or 
minimally cystic kidney tissue, we used publicly avail-
able data from a previous study, and we selected all those 
Ang II-regulated transcripts with statistically significant 
expression determined by significance analysis of micro-
arrays (SAM) with FDR  <  0.05 between cystic and nor-
mal kidney tissues, and we displayed them in a heatmap. 
The expression of Ang II-regulated genes was compared 
to the whole microarray gene set by χ2 test.
Protein–protein interaction (PPI) partners of the Ang 
II-regulated proteins were first identified using Integrated 
Interactions Database (26516188), IID v2016-03 (http://
ophid.utoronto.ca/iid/), selecting only experimentally 
validated partners (including orthologous interaction 
evidence). Ang II-regulated proteins and their PPI part-
ners were then subjected to pathway enrichment analy-
sis. Resulting network was visualized using NAViGaTOR 
v 2.3 (http://ophid.utoronto.ca/navigator) (1937718), and 
the corresponding XML file can be found at: http://www.
cs.utoronto.ca/~juris/data/ClinProteom16/.
Considering the proteins in the network, we used 
pathDIP v1.0 (http://ophid.utoronto.ca/pathDIP) to per-
form pathway enrichment analysis across pathway vari-
ants gathered from major public pathways databases. 
List of 60 most enriched pathways were visualized by the 
barplot.
Results
Expression of Ang II‑regulated genes in kidneys of patients 
with ADPKD
We had previously identified 83 proteins differentially 
regulated by Ang II in primary human proximal tubular 
cells [26]. We first examined the expression of these pro-
teins in kidneys of patients with ADPKD, a type of kidney 
disease in which progression has been linked to Ang II 
activity. A previous study examined gene expression in 
cysts of patients with ADPKD, compared to minimally 
cystic or normal kidney tissue [34]. We found that 47 out 
of 83 (57 %) Ang II regulated proteins significantly (SAM, 
FDR < 0.05) segregated cystic from normal tissues at the 
level of gene expression (Fig. 3). The number of Ang II-
regulated genes found to be differentially expressed in 
cystic tissue was much higher than would be predicted by 
chance alone (χ2 = 108.2, p = 0, for the difference in pro-
portion of differentially expressed genes in Ang II gene 
set compared to the whole Affymetrix set that contained 
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47,400 genes). We then developed SRM methods for 
quantification of 18 Ang II regulated proteins, and 14 of 
these were significantly upregulated in cystic kidney tis-
sue compared to normal tissue (Fig. 3).
Development of an optimized method for urine SRM 
analysis
The steps involved in SRM method development are 
described in methods and displayed in Fig.  1. We first 
Fig. 3 Heatmap of significant differentially expressed Ang II-regulated genes in cystic versus normal kidney tissues. Each column represents one 
tissue sample, and each row represents one gene. Because of several probes, some genes may occupy more than one row. Of 83 genes evaluated, 
47 were differentially expressed (SAM, FDR < 0.05), as shown here. Red colour indicates upregulation and blue indicates downregulation. Red arrows 
point to 14 of 18 genes selected for SRM methods. SC small cysts, MC medium cysts, LC large cysts, MCT minimally cystic tissue, Kidney normal 
kidney tissue
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selected 18 Ang II-regulated proteins most likely to be 
secreted in urine, found to be upregulated in cystic kid-
ney tissue, and those we had previously monitored by 
SRM in human proximal tubular cell lysates (as described 
in methods). The complete list of proteins and peptides 
is shown in Table 1, and modifications and m/z values of 
peptides monitored are listed in Additional file  1: Table 
S2. We next used 26 crude unlabeled synthetic peptides 
(JPT Peptide Technologies) to determine the retention 
times and order of transition intensities, and these are 
displayed in Additional file 1: Table S3, together with the 
previously determined retention times for the remaining 
11 peptides.
In the next step, we spiked in BSA protein prior to 
urine protein concentration, to determine method repro-
ducibility and recovery. We processed two urine samples 
(1 female and 1 male; subjects 1 and 2 in Additional file 1: 
Table S1) with four different methods and compared pep-
tide concentrations. These four methods included com-
binations of (1) protein precipitation using 3  kDa-filter 
(Amicon) or acetonitrile, and (2) protein digestion with 
Lys-C/trypsin or trypsin alone (Fig.  1). After digestion, 
samples were divided into aliquots each containing 20 μg 
of total protein, and three heavy-labeled peptides (three 
proteotypic peptides of BSA) were spiked in at a concen-
tration of 100 fmol/μl. Each aliquot was subjected to C18 
microextraction and analyzed on triple-quadrupole mass 
spectrometer (TSQ-Quantiva). Three BSA peptides were 
used to assess reproducibility and recovery (Table  2). 
Technical triplicate CVs (same sample injected three 
times on the instrument) were ≤6  % for BSA peptides, 
for each method (Table 2). BSA protein recovery was cal-
culated by averaging the recovery of three BSA peptides. 
The recovery was 119 % in sample 1 and 112 % in sample 
2, when precipitated with acetonitrile and digested with 
LysC/trypsin. Amicon filter concentration followed by 
LysC/trypsin digestion yielded BSA recovery of 171 % for 
sample 1 and 140 % for sample 2. Recovery >100 % may 
be explained by inaccurate quantification of spiked-in 
BSA, or perhaps by the carryover effect of BSA peptides 
used as QC. Trypsin digestion demonstrated inferior 
results. Acetonitrile precipitation followed by trypsin 
digestion demonstrated BSA recovery of 67  % for urine 
1 and 64 % for urine 2. Amicon filter concentration fol-
lowed by LysC/trypsin digestion yielded BSA recovery of 
63 % for sample 1 and 44 % for sample 2. Protein precipi-
tation with acetonitrile followed by Lys-C/trypsin diges-
tion enabled detection of most Ang II-regulated peptides 
(13 of 37) in urine samples 1 and 2. Given the detection 
of the highest number of peptides of interest, we then 
applied acetonitrile precipitation combined with Lys-C/
trypsin digestion to analyze urine samples from patients 
with ADPKD.
Ang II‑regulated peptides detected in urine samples 
from controls and ADPKD patients
Using methods developed with the help of crude unla-
beled peptides spiked into urine, we next monitored 37 
peptides corresponding to 18 Ang II-regulated proteins 
in nine urine samples from ADPKD patients and two 
controls. We monitored both unmodified and modi-
fied forms (see below) of peptides. Using retention times 
and order of transitions derived with the use of crude 
peptides, we identified 13 peptides in all urine samples 
(Table 1). Peptide was considered present in urine if there 
was coelution of at least 4/6 or 5/7 transitions in the 
correct order and at the correct retention time. Heavy-
labeled peptides for absolute quantification containing a 
trypsin-cleavable tag were thus purchased, correspond-
ing to these 13 peptides. They were spiked in urine sam-
ples prior to tryptic digestion, and both heavy-labeled 
and light forms were monitored.
Chemically modified peptides in urine samples 
from controls and ADPKD patients
In addition to unmodified peptides, we monitored pep-
tide modifications including glutamine and asparagine 
deamidation, and methionine oxidation. Deamidation is a 
post-translational modification that may occur as a result 
of protein/peptide aging. Here, however, deamidation is 
most probably an artifact of sample preparation such as 
protein denaturation and treatment with acidic solutions 
(0.1 % formic acid). We first monitored deamidations in 
the control urine samples in order to determine whether 
these modifications contribute meaningfully to the total 
peptide area. Deamidation was present in both light and 
heavy-labeled peptides, whenever light peptides were 
detectable. It was detected in both light and heavy forms 
in the following peptides: GGVNDNFQGVLQNVR 
(TSP-1), TIVTTLQDSIR (TSP-1), GFFADYEIPNLQK 
(BST1), and IQAYDYLECSAK (RHOB). As a general 
rule, multiple deamidations in the same peptide did not 
significantly contribute to the overall peptide area (Addi-
tional file  1: Table S4). As noted in Additional file  1: 
Table S4, doubly and triply deamidated forms of peptide 
GGVNDNFQGVLQNVR accounted for <3 % of the total 
peptide area. Deamidations closer to the N-terminus of 
the peptide contributed to 50 % of the total peptide area, 
and only these modifications were selected for monitor-
ing in all urine samples. The total H/L ratio was changed 
by 3–4 % when including all modified forms. In case of 
peptide GFFADYEIPNLQK, singly deamidated forms 
accounted for approximately 30–37  % of the total pep-
tide areas, while doubly deamidated forms constituted 
3.5–6  % of the unmodified peptide areas (Additional 
file 1: Table S4). The total H/L ratio was changed by 12 % 
due to the inclusion of deamidated forms. We decided 
Page 10 of 19Konvalinka et al. Clin Proteom  (2016) 13:16 
to monitor all deamidated forms of this peptide. Deami-
dated peptide TIVTTLQDSIR accounted for 28 % of the 
total heavy-labeled peptide area, and 33–36 % of the total 
light peptide area. H/L ratio was changed by 7  % when 
including deamidated forms. Finally, deamidated form of 
peptide IQAYDYLECSAK was responsible for 20 % of the 
total heavy peptide area, and 10–30  % of the total light 
peptide area. H/L ratio was changed by 12 % when includ-
ing deamidated forms (Table 3). Heavy peptides were sta-
ble, displaying predictable degree of deamidation across 
samples. In contrast, light peptides displayed higher and 
more variable degree of deamidation (Table 3). As a rule, 
deamidation contributed minimally to total peptide con-
centrations. The median % change in total peptide con-
centration as a result of deamidation was ≤7 % for TSP1 
peptides and 12 % for BST1 and RHOB peptides.
We had a single peptide VAGTGEGGLEEMVEEL 
NSGK (DBNL) with methionine. This amino acid is 
particularly susceptible to oxidation as a result of sam-
ple storage. Both mono-oxidized and di-oxidized forms 
have been described. We initially noted a peak in most 
ADPKD urine samples due to the mono-oxidized form. 
However, the heavy peptide had no such oxidized forms, 
although it eluted at a similar retention time. We tried 
to reverse methionine oxidation by adding 1 µl of 0.3 M 
methionine solution to 20  µg peptide fractions. This 
failed to result in the reversal. We then injected two C18 
microextracted peptide fractions on Q-Exactive mass 
spectrometer in LC–MS/MS fashion, and could not iden-
tify a light spectrum of oxidized or non-oxidized peptide 
VAGTGEGGLEEMVEELNSGK (albeit in non-fraction-
ated urine samples). We thus abolished monitoring of 
this peptide.
Analytical parameters of Ang II‑regulated peptides 
quantified in urine
We next determined the analytical parameters of Ang 
II-regulated peptides. When heavy and light peptides 
were monitored, we discovered that peptides VAGTGEG 
GLEEMVEELNSGK, IFPYEEYASWK, EALCGCSINVP 
TLDGR, SSGDYSATFLPGLIPAEK, EISDGDVIISGNK, 
GGGDQGYGSGR could not be confidently identified, 
due to the absence of co-elution of heavy and light pep-
tides. The remaining seven peptides were confidently 
identified, and we proceeded to analyze them. We uti-
lized urine samples from two controls and one ADPKD 
subject to generate calibration curves, and calculate LOD 
and LOQ for each peptide. Calibration curves were gen-
erated from H/L peptide ratios determined by spiking 
heavy-labeled peptides into aliquots of the same urine 
Table 2 Recovery and  coefficients of  variation (CVs) of  3  pmol of  BSA protein and  its proteotypic peptides in  technical 
triplicates of two urine samples, utilizing four methods as described in the text
a Mean ± SD
Protein/peptides Mean recovery—urine 1  
(pmol)a





 LVNELTEFAK 6.137 ± 0.124 2.0 5.011 ± 0.08 1.7
 HLVDEPQNLIK 6.242 ± 0.058 0.9 4.852 ± 0.059 1.2
 LGEYGFQNALIVR 3.046 ± 0.056 1.8 2.770 ± 0.030 1.1
Method 2—Amicon/Tryp
BSA
 LVNELTEFAK 2.061 ± 0.017 0.8 1.36 ± 0.064 4.7
 HLVDEPQNLIK 2.317 ± 0.071 3.1 1.52 ± 0.037 2.4
 LGEYGFQNALIVR 1.308 ± 0.011 0.8 1.044 ± 0.012 1.1
Method 3—Acetonitrile/LysC-Tryp
BSA
 LVNELTEFAK 4.400 ± 0.029 0.7 3.980 ± 0.213 5.3
 HLVDEPQNLIK 4.568 ± 0.119 2.2 3.984 ± 0.058 1.5
 LGEYGFQNALIVR 1.768 ± 0.026 1.5 2.124 ± 0.013 0.6
Method 4—Acetonitrile/Tryp
BSA
 LVNELTEFAK 2.00 ± 0.005 0.2 1.950 ± 0.010 0.5
 HLVDEPQNLIK 3.46 ± 0.098 2.9 2.280 ± 0.130 5.8
 LGEYGFQNALIVR 0.592 ± 0.005 0.9 1.535 ± 0.011 0.7
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sample, at concentrations: 1000 (only for some peptides 
with higher estimated concentration in urine), 100, 10, 
1, 0.1 and 0 fmol/μl. Each point on the calibration curve 
was generated by duplicate or triplicate injections. Addi-
tional file  1: Figure S1 A–G displays calibration curves 
of the seven monitored peptides. As noted in Additional 
file 1: Figure S1, all peptides demonstrated excellent lin-
earity with R2 > 0.99. LYPLA1 peptide demonstrated lin-
earity with R2 > 0.97.
We next analyzed within-run and between-run vari-
ability. Table  4 displays mean within-run and between-
run variability for each individual peptide in two control 
and nine ADPKD urine samples. Overall, within-run CV 
was <10 %. Between-run CV takes into account variation 
due to sample preparation. We noted higher between-
run CVs compared to within-run CVs, although not for 
peptide LYPLA1 (CV was 6  %). We then explored the 
reasons for this variability. BSA protein spiked at the very 
beginning of sample preparation enabled better under-
standing of the contribution of variability in sample prep-
aration to overall results. As Fig. 2 displays, BSA protein 
was added at the beginning of sample preparation, at a 
constant amount, to all urine samples containing the 
same amount of total protein, while its heavy peptides 
were added at the very end, just prior to C18 microextrac-
tion. Any alterations in L/H BSA peptide ratios may be a 
result of protein loss during sample preparation. Adjust-
ment of peptide concentrations by BSA did not account 
for variability in all samples or for all peptides, as evident 
from Additional file  1: Figure S2. For example, samples 
1 and 167 still displayed peptide measurements with 
poor between-run correlation. Also, peptides of GLNA 
(GLUL) and TSP1 proteins displayed poor between-run 
correlation in several samples. We thus concluded that 
adjustment by BSA was not justified, but still used L/H 
BSA ratio as an indicator of overall sample integrity.
LOD was calculated as previously described [35, 36] by 
taking the average of blank injections and adding three 
standard deviations to the mean. Similarly, LOQ was cal-
culated by taking the average of blank injections and add-
ing 10 standard deviations to the mean. In two cases, LOD 
and LOQ could not be calculated from linear regression 
Table 3 Deamidated peptides monitored and their contribution to the overall peptide areas and ratios
Mean % of heavy peptide deamidations, % of light peptide deamidations and % change in concentration (due to the modified forms) for each peptide, and across all 
urine samples is shown
Protein/peptide L/H ratio formula


























20 ± 0.9 15 ± 14.8 12
730.8+731.3
734.8+735.3
Table 4 Peptide analytical parameters including within-run, between-run CV, LOD and LOQ
Within-run and between-run CVs are presented as means of 11 urine samples for each peptide
a LOD and LOQ could not be determined from statistical methods for this peptide. They were extrapolated from the calibration curve












TSP-1 TIVTTLQDSIR 4.6 28 1.1 0.40 1.2 0.43
TSP-1 GGVNDFQGVLQNVR 4.7 32 1.3 0.43 2.3 0.75
GLUL LVLCEVFK 8.4 16 0.17 0.06 1.1 0.39
RHOB IQAYDYLECSAKa 7.6 24 0.1 0.04 0.1 0.04
BST1 GFFADYEIPNLQK 2.6 32 0.14 0.05 0.48 0.17
LYPLA1 LAGVTALSCWLPLRa 4.4 6 0.1 0.04 1.0 0.40
LAMB2 GSCYPATGDLLVGR 3.7 37 1.04 0.34 1.20 0.39
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equation. In this case, LOD was estimated as the minimal 
amount of heavy peptide significantly different from the 
blank injection. LOQ was estimated as minimal amount 
of heavy peptide measured within the linear response 
range of H/L peptide ratio of the calibration curve [37]. 
Table 4 displays LOD and LOQ for each peptide.
Quantification of Ang II‑regulated peptides in urine 
samples
In order to quantify Ang II-regulated peptides in relevant 
urine samples from 11 controls, 17 patients with ADPKD 
and 9 patients with CKD (Additional file  1: Table S1), 
we selected three top transitions of each peptide, and 
ran methods for each sample in duplicates (within-run 
replicates). The methods are shown in Additional file 1: 
Table S5. We calculated the mean peptide excretion rate 
of within-run replicates for each sample and adjusted it 
by urine creatinine. TSP1 protein was quantified by two 
different peptides, and urine excretion rates between the 
two peptides showed excellent linear correlation with 
R2  =  0.86 (Additional file  1: Figure S3). Three samples 
had LYPA1 levels below LOQ. The number of peptide 
measurements below LOD was <2 %.
 We found that urine excretion rate of all proteins fol-
lowed the same pattern, with the lowest excretion rates 
in patients with ADPKD and the highest excretion rates 
in patients with CKD (Figs. 4, 5). The urine excretion rate 
of most proteins was significantly different between the 
three disease groups: BST1 (p = 0.008, ANOVA), LAMB2 
(p  =  0.021, ANOVA), LYPA1 (p  =  0.012, ANOVA), 
RHOB (p  =  0.021, ANOVA), and TSP1 (p  =  0.013 for 
peptide 1 and p = 0.019 for peptide 2, ANOVA). Post-hoc 
analysis demonstrated that in all cases there was a statis-
tically significant difference between ADPKD and CKD 
groups, and in case of BST1, there was also a statistically 
significant difference between CKD and control groups.
We then examined associations between urine excre-
tion rate of Ang II-regulated proteins and clinical char-
acteristics, such as measures of kidney function including 
serum creatinine (sCr), total kidney volume, sex, age, 
and disease group of our patients. There was no corre-
lation between urine excretion rates of Ang II-regulated 
proteins and sCr, total kidney volume, or age. However, 
univariate analysis demonstrated significant association 
between urine excretion rates of all proteins and sex, as 
well as disease group (Additional file 1: Table S6). In all 
cases, urine excretion rate of Ang II-regulated proteins 
was higher in females compared to males. GLNA dem-
onstrated striking association with sex (p  =  1.10E−05, 
two sample t test), but no significant association with 
disease group (p = 0.074, ANOVA). BST1 demonstrated 
the strongest association with disease group (p = 0.008, 
ANOVA).
Finally, we performed multivariate analysis using mul-
tiple correspondence analysis (MCA) on protein concen-
tration and clinical data including sex and age, where all 
protein concentrations as well as age were first discre-
tized into four levels each, in a way that preserves equal 
frequencies between levels (Fig. 6). Only two controls had 
information about age, so only those could be included. 
Interestingly, samples 77 and 54 represent CKD patients 
with unknown etiology of renal disease and without pro-
teinuria or renal dysfunction. Samples 91 and 119 rep-
resent patients with medullary sponge kidney, a form of 
kidney disease with medullary cysts, without proteinuria 
or renal dysfunction. Finally, the right upper corner con-
tains a cluster of patients with IgA nephropathy, associ-
ated with proteinuria and/or impaired kidney function. 
The two PKD patients 323 and 117 have proteinuria or 
impaired renal function with large kidneys, suggest-
ing advanced disease. The analysis demonstrates good 
separation between ADPKD and CKD patients, and thus 
suggests that urine excretion rate of Ang II-regulated 
proteins in conjunction with sex and age can distinguish 
ADPKD and CKD patients.
Lastly, to obtain biological context of the six proteins, 
we first mapped them to protein interaction network 
(Additional file  1: Figure S4), and then conducted the 
pathway enrichment analysis (Additional file  1: Figure 
S5). Taking the 6 monitored proteins, we have queried 
IID database to obtain network of immediate, physically 
interacting proteins. The resulting network comprised 
226 proteins and 1575 interactions (Additional file 1: Fig-
ure S4). Six query proteins are highlighted as rectangles. 
None of them directly interact, but all interact via seven 
proteins—nodes highlighted with red outline, and edges 
made thicker. While five proteins link only pair of query 
proteins, ELAV1 links three and 1433E links all six pro-
teins. 1433E is also the most central node in the network 
(as determined by all pairs shortest path analysis).
Discussion
We have developed SRM assays for quantification of 
urine excretion rate of previously discovered Ang II-
regulated proteins, in order to address a clinically unmet 
need, namely, the lack of markers of kidney Ang II activ-
ity. Our main objectives were: (1) to develop methods 
for urine-based quantification of kidney Ang II activity 
proteins; (2) to optimize peptide quantification in urine 
samples, and (3) to demonstrate the potential relevance 
of Ang II-regulated proteins in patients with ADPKD and 
CKD. These optimized SRM assays have the potential to 
serve as a clinical tool for assessment of kidney Ang II 
activity in patients with chronic kidney diseases.
Ang II-regulated proteins were discovered in kidney 
cells in  vitro, and validated in animal models of kidney 
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disease in vivo [26, 27]. The role of RAS and Ang II in the 
progression of ADPKD and CKD had been established. 
We first developed SRM-based methods for quantifica-
tion of Ang II-regulated proteins in human urine. SRM 
has emerged as an optimal method for specific, mul-
tiplexed, and cost-effective quantification of proteins 
in tissue and biofluids [28, 36–38]. Prior studies utiliz-
ing SRM for quantification of urine proteins have been 
reported [28, 35, 39, 40]. These studies typically applied 
different methods for protein precipitation, and diges-
tion with two enzymes was not tested. Other studies 
applied depletion of abundant proteins [41]. The latter 
approach is suboptimal, as depletion strategies are likely 
to result in loss of analytes of interest, in addition to add-
ing complexity and increasing the time required for sam-
ple processing. The strength of our approach includes: 
(1) elucidation of an optimal sample preparation method 
without the need for sample fractionation of depletion of 
abundant proteins, (2) monitoring of post-translational 
modifications in urine, and (3) demonstration of poten-
tial relevance of these proteins in clinical disease.
We found that combination of digestive enzymes was 
more critical than the choice of protein concentration 
strategy. This likely relates to enhanced digestion with 
Fig. 4 Absolute quantification of Ang II-regulated proteins in urine of healthy controls, patients with polycystic kidney disease (PKD) and chronic 
kidney disease (CKD). Values are expressed in log2 transformed fmol/µmol of creatinine. a BST1, b LAMB2, c GLNA, d LYPA1
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multiple enzymes. Furthermore, urine processing is prob-
lematic since protein concentration is a necessary step 
prior to subsequent analyses, given that urine is a dilute 
biofluid. In order to anticipate the losses associated with 
urine processing, we introduced purified, full-length BSA 
protein. This exogenous standard enabled determination 
of the recovery of BSA protein and thus the integrity of 
the sample processing. Similar approaches to assessment 
of yield and reproducibility were applied before [35, 42].
Peptide modifications should be considered when per-
forming quantitative analyses, since peptides may acquire 
these modifications in unpredictable fashion [43, 44]. 
These modifications arise as a consequence of protein/
peptide aging, or represent artifacts of sample process-
ing [43, 44]. We monitored peptides with glutamine con-
version to glutamic acid, and asparagine conversion to 
aspartic acid. These modifications may serve as ‘molecu-
lar clocks’ of protein aging and turnover [45]. We dem-
onstrated increased rates of deamidated endogenous 
peptides, compared to synthetic ones, and this was previ-
ously described [43]. Some of our peptides had more than 
one potential deamidated site, and we noted that in these 
cases, single deamidations and N-terminal site modifica-
tions tended to predominate. This is not surprising, since 
Fig. 5 Absolute quantification of Ang II-regulated proteins in urine of healthy controls, patients with polycystic kidney disease (PKD) and chronic 
kidney disease (CKD). Values are expressed in log2 transformed fmol/µmol of creatinine. a RHOB, b TSP1—1st peptide and c TSP1—2nd peptide
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peptide amino acid sequence surrounding the glutamine 
or asparagine residues determines the likelihood of mod-
ification [46]. Importantly, heavy peptides appeared to 
have a stable rate of deamidation, which varied between 
20 and 35  %, but was consistent for any given peptide. 
Light peptides coming from urine samples had more 
variability in the rate of deamidation. This likely reflects 
the ‘molecular clock effect’, given that urines came from 
different individuals, and had been collected at differ-
ent times. Quantification of deamidated peptide forms is 
often ignored in SRM studies, and our approach to moni-
toring then should be applied to other SRM studies that 
include peptides with potential deamidation sites.
We used BSA protein and the corresponding heavy-
labeled peptides to assess different sample processing 
methods, and similar approaches had been reported pre-
viously, using non-human proteins spiked into urine [35, 
42]. Variable recovery of BSA protein that we noticed 
might be explained by the carry-over effect of BSA pep-
tides used as QCs. As such, more ideal internal standards 
could constitute other non-human proteins with corre-
sponding heavy peptides, or pairs of light and heavy pep-
tides that cover the entire range of hydrophobicities and 
that are not used in QC. Such proteins and peptides may 
prove useful when adjusting for any losses during sample 
processing.
Our last objective was to test the relevance of Ang II-
regulated protein measurements in urine of patients 
with chronic kidney diseases. We quantified Ang II reg-
ulated proteins in urine of patients with ADPKD, CKD 
and healthy controls. Interestingly, all proteins displayed 
the same direction of change in urine samples, with the 
highest excretion rate in CKD and the lowest in ADPKD 
patients. The CKD group consisted mainly of patients 
with IgA nephropathy, a kidney disease where progres-
sion was strongly linked to kidney Ang II activity [47–49]. 
It is notable that this group of patients had the highest 
rate of proteinuria (Additional file 1: Table S1), support-
ing the notion that kidney Ang II was active. It is inter-
esting that ADPKD patients had the lowest levels of Ang 













































Fig. 6 Multivariate analysis using multiple correspondence analysis (MCA) on protein concentration and clinical data including sex and age, where 
all protein concentrations as well as age were first discretized into four levels each, in a way that preserves equal frequencies between levels. Good 
separation between CKD and PKD patients is evident
Page 16 of 19Konvalinka et al. Clin Proteom  (2016) 13:16 
II-regulated protein excretion rates. We found that at the 
level of mRNA, the majority of Ang II-regulated proteins 
displayed significantly increased expression in kidney 
cysts compared to normal tissue. Similarly, prior studies 
of kidney tissue and cysts from patients with polycystic 
kidney disease demonstrated convincing increases of 
RAS components, including Ang II [21, 50, 51]. RAS and 
Ang II activity accelerated cyst growth through produc-
tion of mitogenic factors and hypertension [52–55]. It is 
however known that renal cysts could become walled off 
and lose communication with the tubules. Prior studies 
support this notion by showing that inflammatory mark-
ers highly expressed in ADPKD cysts are excreted in 
urine at relatively low levels [56]. It is thus possible that 
our Ang II-regulated proteins had decreased excretion in 
ADPKD urine because of loss of communication between 
cysts and the tubules.
We found a strong association between sex and urine 
excretion rate of Ang II-regulated proteins. It has long 
been recognized that male sex predisposes to kidney dis-
ease progression and that there are differences in RAS 
activity between the sexes [57–60]. Whether this differ-
ence reflects differential protein expression in the kidney 
is unknown and will be addressed in future studies.
Protein that was most significantly associated with 
disease groups was BST1. BST1 (bone marrow stro-
mal antigen-1) is an enzyme, ADP-ribosyl cyclase, that 
converts NAD+ to cyclic ADP ribose, which activates 
calcium signaling and promotes proliferation in hemat-
opoietic cells [61]. This is somewhat analogous to inosi-
tol-1,4,5-triphosphate (IP3), which is produced upon Ang 
II-mediated signaling, and which releases calcium from 
the sarcoplasmic reticulum. BST1 is expressed in the 
normal human kidney, mostly in proximal tubular cells 
(Human Protein Atlas). However, its function in the kid-
ney is unknown. It is worth mentioning that RHOB and 
TSP1 were implicated in Ang II-mediated effects. RHOB 
is involved in Rho GTPase signaling, and was found to be 
upregulated by Ang II in adrenocortical cells [62]. TSP1 
is a profibrotic protein, capable of binding to fibrino-
gen, fibronectin, collagen and integrins. TSP1 antagonist 
blocked cardiomyopathy induced by high Ang II in rats 
[63]. In renal mesangial cells, Ang II-induced activation 
of latent TGFβ1 was dependent on p38MAPK and JNK 
signaling via TSP1 [64]. Finally, in a mouse model of uni-
lateral ureteral obstruction, Ang II infusion resulted in 
intense tubular deposition of TSP1, which was linked to 
tubulointerstitial fibrosis [65]. TSP1 may thus represent 
an important cellular signal for Ang II induced fibrosis. 
It is plausible that quantified proteins participate in the 
chronic mechanisms of kidney injury that involve fibrosis, 
proliferation and response to injury, mechanisms linked 
to Ang II bioactivity. The role of these proteins in ADPKD 
and CKD should be further explored in the future.
Lastly, the proteins quantified displayed enrichment 
in the same biological processes and pathways enriched 
among the original 83 proteins [26], namely profibrotic 
pathways such as TGFβ, plasminogen and PDGF sign-
aling, Rho protein signal transduction, ERK and MAPK 
signaling and inflammation (Additional file 1: Figure S5). 
While none of the 6 proteins interacted directly, they 
were all connected via 7 proteins (Additional file 1: Fig-
ure S4), and protein 1433E connected all 6 Ang II-regu-
lated proteins. 1433E is an adaptor protein implicated in 
metabolism, PI3K and GPCR signal transduction, apop-
tosis and cell cycle regulation. All of these processes were 
significantly enriched by Ang II in kidney cells [1], sug-
gesting that 1433E may in fact link Ang II signaling to all 
six proteins monitored in urine.
Our study has several strengths, including develop-
ment of a method for quantification of Ang II-regulated 
proteins that is readily translatable into the clinic. We 
have performed careful method optimization, and 
we monitored modified forms of peptides. We offer a 
workflow for quantification of urine proteins that can 
easily be adapted to the study of any urine analyte. 
Finally, proteins monitored appear to differentiate kid-
ney disease groups and may have relevance in clinical 
populations.
 Notwithstanding these strengths, there are some 
limitations. Data regarding age were missing from most 
healthy controls. Orthogonal measures of Ang II-regu-
lated proteins were not performed. Finally, we have ana-
lyzed a small number of samples in this pilot study. The 
study will be expanded to a larger population of patients 
with kidney diseases in the future.
Conclusions
In summary, we have developed methods for SRM-based 
quantification of Ang II-regulated proteins in human 
urine, and we demonstrated that urine excretion rates of 
these proteins carry meaningful information about kid-
ney disease type. Future studies will examine whether 
these proteins represent coveted markers of kidney Ang 
II activity in larger cohorts of patients with chronic kid-
ney disease.
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shown on the top left. Figure S2. Between-run variability of L/H peptide 
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represents one urine sample) and B) peptides (each box represents one 
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measure of between-run variability, and perfectly reproducible measure-
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of 0. Figure S3. Linear correlation between urine excretion rates of two 
peptides of TSP1. Peptide 1 measurements are presented on x-axis, while 
peptide 2 measurements are on y-axis. Figure S4. Protein-protein interac-
tion network including the 6 monitored proteins and their direct interac-
tion partners and interaction among them. Physical protein interactions 
obtained from IID v2016-03 (26516188), and visualization performed in 
NAViGaTOR 2.3 (19837718). Query proteins are highlighted as rectan-
gles. Nodes with red signify the shortest path connection among query 
proteins. Node color represent biological function, as per legend. All other 
nodes and edges are partially transparent to reduce network clutter. Cor-
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data/ClinProteom16/. Figure S5. Pathway enrichment analysis among 
the 6 monitored proteins and their PPI partners from Figure S4 using 
pathDIP ver. 1.0. Only top 60 most significantly enriched pathways taken 
from sources listed to the right of the graph are displayed. Note, p-values 
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to allow their log10 transformation for visualization purposes, those were 
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